Fig. 4

Evaluation of potential immunotoxicity in in vivo assays. a-c DBA/1 mice were immunized with glucose-6-phosphate isomerase (G6PI) + complete Freund’s adjuvant and exposed to treatment daily for 31 days. a Red blood cell counts and leucocyte counts in peripheral blood. b Splenocyte numbers. c Numbers of CD4⁺ T cells (CD3⁺CD4⁺CD8⁻) and B cells (CD3⁻CD19⁺MHCII⁺) in spleens. d-f CD-1 mice were treated from day −14 to 14 and immunized with keyhole limpet hemocyanin (KLH) on day 0 (T cell-dependent antibody response (TDAR) assay). d Red blood cell counts in peripheral blood. e Numbers of CD4⁺ T cells (CD3⁺CD4⁺CD8⁻) and B cells (CD3⁻CD19⁺MHCII⁺) in the spleen. f Levels of KLH-specific IgM and IgGs in plasma at day 7 and 14, respectively. Graphs show mean (+ standard error of the mean) for 3–6 mice/group, *p <0.05 versus vehicle control, ^# p <0.05 versus non-immunized and untreated group (naive). N naive, Veh vehicle, JAKi Janus kinase inhibitor, SYKi spleen tyrosine kinase inhibitor, Pred prednisolone